Vemurafenib is an oral small molecule kinase inhibitor that selectively targets BRAFV600E mutant kinase and exerts anti-tumor effects by inhibiting the MAPK signaling pathway.

1、 Drug name

Vemurani (trade name: ZELBORAF)

2、 Indications

Used to treat BRAFV600E mutation positive, unresectable, or metastatic melanoma patients confirmed by FDA approved testing methods.

Not recommended for patients with wild-type BRAF melanoma.

3、 Specifications

Specification: Film coated tablets, each containing 240mg of Vimafenib.

4、 Main components

Active ingredient: Vimafenib

5、 Usage and dosage

Recommended dosage: 960mg (4 tablets) orally, twice daily (with an interval of about 12 hours between morning and evening).

Usage: Swallow the whole tablet, do not chew or crush, can be taken with food or on an empty stomach.

6、 Dose adjustment

When symptomatic adverse drug reactions or QTc interval prolongation occur, medication should be reduced, interrupted, or discontinued.

First adjustment: Discontinue treatment until symptoms improve and switch to 720mg twice daily.

Secondary adjustment: After interrupting treatment, change to 480mg twice daily.

It is not recommended to reduce the dosage to below 480mg twice a day.

7、 Medication precautions

Before and after meals: can be taken with food or on an empty stomach.

Omission treatment: If the dosage is missed, it can be taken within 4 hours before the next administration and should not be taken twice at the same time.

Vomiting treatment: If vomiting occurs after taking medication, there is no need to take additional medication, and medication should continue according to the original plan.

Other precautions:

During treatment, it is necessary to avoid light and wear protective clothing and apply broad-spectrum sunscreen (SPF ≥ 30) when going out.

Severe skin reactions or hypersensitivity reactions require permanent discontinuation of medication.

8、 Medication for special populations

Pregnant women: May cause harm to the fetus, effective contraception is necessary during medication.

Breastfeeding period: Breastfeeding should be stopped during medication.

Liver and kidney dysfunction: No dose adjustment is required for mild to moderate cases, but caution should be exercised when using severe cases.

Children: The safety and efficacy of patients under 18 years old have not been established.

Elderly people may be more prone to adverse reactions such as skin squamous cell carcinoma and nausea.

9、 Adverse reactions

Common adverse reactions (≥ 30%) include joint pain, rash, hair loss, fatigue, photosensitivity, nausea, itching, and skin papillomatosis.

Other factors include elevated liver enzymes, prolonged QT interval, and ocular reactions (such as uveitis).

10、 Contraindications

There are no clear contraindications.

11、 Drug interactions

Avoid co administration with drugs that are metabolized by CYP1A2, CYP2D6, CYP3A4 and have a narrow therapeutic window.

INR monitoring needs to be strengthened when combined with warfarin.

Caution should be exercised when using strong CYP3A4 inhibitors or inducers in combination.

12、 Storage method

Store in a room temperature environment of 20 ° C-25 ° C, allowing fluctuations within the range of 15 ° C-30 ° C.

Keep the original packaging bottle cap tightly closed.

Vemurafenibinformation